DGAP-News: mutares sells Suir Pharma Ireland

DGAP-News: mutares AG / Key word(s): Mergers & Acquisitions/Private
Equity
mutares sells Suir Pharma Ireland

23.06.2015 / 09:40

---------------------------------------------------------------------

The Munich-based restructuring specialist mutares AG (ISIN: DE000A0SMSH2)
has sold the pharmaceutical contract manufacturer Suir Pharma Ireland to
the strategic investor Saneca Pharmaceuticals. With its second successful
exit in 2015, mutares further streamlines its portfolio.

Suir Pharma Ireland (SPI) was acquired in 2012 from German STADA Group. It
operates as a Contract Manufacturing Organisation (CMO) producing finished
dosage formulations across a broad range of therapeutic areas for various
customers worldwide and operates the only Independent Beta-Lactam FDA
approved facility in Europe.

After successfully accomplishing the main challenge of making SPI a
stand-alone pharmaceutical contract manufacturer, mutares has decided to
sell SPI to Saneca Pharmaceuticals for an undisclosed amount. Hence,
mutares continues to streamline its portfolio and to free up capacities for
new transactions as the deal pipeline is very promising.

Saneca Pharmaceuticals is confident that this strategic acquisition will
add significantly to the services that the Saneca Group can offer to its
customers. Lubo Soltys, President of Saneca, commented: "We are delighted
to have acquired Suir Pharma. We see the combined entity providing
significantly enhanced pharmaceutical development capacity and tech
transfer capabilities across a range of pharmaceutical forms. This will
certainly provide easier access to various markets for our worldwide
customer base."

Company profile of Saneca Pharmaceuticals

Saneca Pharmaceuticals is a supplier to the global pharmaceutical and
healthcare industry. Saneca develops and produces high quality
pharmaceutical dosage forms, including oral solid, liquids, soft gel
capsules and creams. In addition, Saneca Pharmaceuticals has a portfolio of
synthetic API's, and opiate API's produced from plant biomass.

Company profile of mutares AG

mutares AG, Munich (www.mutares.de), acquires companies, that are being
sold in the course of a repositioning process at their owners and that show
a clear operational improvement potential. Getting engaged with its own
teams, mutares actively supports its portfolio companies to achieve a clear
value increase. The focus of the operational work is to ensure sustainable,
long-term growth. The shares of mutares AG are traded in the Open Market of
the Frankfurt Stock Exchange (Entry Standard) under the symbol MUX (ISIN:
DE000A0SMSH2).

For further information, please contact:

mutares AG
Christoph Himmel
Investor Relations & Corporate Communications
Tel. +49 89 9292776-0
Fax +49 89 9292776-22
[email protected]
www.mutares.de

 

---------------------------------------------------------------------

23.06.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


370845 23.06.2015
Retrieved from "http://globenewswire.com/news-release/2015/06/23/746553/0/en/DGAP-News-mutares-sells-Suir-Pharma-Ireland.html"

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.